Please wait while your page loads ...
On Monday, October 25, 2021
Design Therapeutics is developing gene targeted chimeras (GeneTACs™), which are designed to target the underlying cause of inherited nucleotide repeat expansion diseases to potentially modify the course of disease. The FA program is expected to begin a Phase 1 clinical trial in the first half of 2022 for people affected with Friedreich’s ataxia, age >18 years old.
Please join FARA and Design Therapeutics for an informational webinar on Monday, October 25, 2021, at 7:00 PM Eastern.
Register for the Zoom webinar today by clicking the button below. After registering, you will receive a conformation email containing the link to tune in on October 25th.